Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nebius Group NV (NBIS) vs Smith & Nephew plc (SNN) Price & Performance

Nebius Group NVTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Nebius Group NV vs Smith & Nephew plc — how do they compare? Nebius Group NV trades at $234.34 (market cap $66.30B), while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: Nebius Group NV is far larger — about 5.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.85% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.

NBISSNN
Market Cap
$66.30B$11.63B
Sector
TechnologyHealth
52-Week High
$286.69$38.53
52-Week Low
$73.87$27.80
Enterprise Value
$68.43B$14.66B
Dividend Yield
2.85%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nebius Group NV

NBIS stock surged 7.73% to $243.88 following a strategic partnership announcement with Palantir as its preferred sovereign AI infrastructure partner. The stock trades near its pivot point of $244 with bullish technical indicators and strong analyst support (80% buy ratings). Despite high valuation multiples (P/E 74.61, P/S 49.83), the company shows improving earnings trends with recent quarterly beats and projected revenue growth from $530M to $1.4B in 2026.

The outlook remains positive with a consensus price target of $291.33 (19% upside), driven by AI infrastructure demand and the Palantir partnership. Key risks include stretched valuations, negative operating cash flow relative to investments, and execution challenges in scaling capacity. The stock presents growth potential but requires careful monitoring of profitability improvements and contract execution.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.

Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nebius Group NV

Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.

Read more on NBIS

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN